Schaub, Christina; Kebir, Sied; Junold, Nina; Hattingen, Elke; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Niessen, Michael; Mack, Frederic; Stuplich, Moritz; Tzaridis, Theophilos; Bähr, Oliver; Kortmann, Rolf-Dieter; Schlegel, Uwe; Schmidt-Graf, Friederike; Rohde, Veit; Braun, Christian; Haenel, Mathias; Sabel, Michael; Gerlach, Rüdiger; Krex, Dietmar; Belka, Claus; Vatter, Hartmut; Pröscholdt, Martin; Herrlinger, Ulrich; Glas, Martin (2018): Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. In: Journal of Cancer Research and Clinical Oncology, Vol. 144, No. 8: pp. 1581-1589 |
Abstract
We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial. In 142 patients (94 BEV/IRI, 48 TMZ), we reviewed magnetic resonance imaging scans at baseline and first tumor recurrence. Based on contrast-enhanced T1-weighted and fluid-attenuated inversion recovery images, we assessed tumor growth patterns and tumor invasiveness. Tumor growth patterns were classified as either multifocal or local at baseline and recurrence;at first recurrence, we additionally assessed whether distant lesions appeared. Invasiveness was determined as either diffuse or non-diffuse. Associations with treatment arms were calculated using Fisher's exact test. At baseline, 115 of 142 evaluable patients (81%) had a locally confined tumor. Between treatment arms, there was no significant difference in the fraction of tumors that changed from an initially local tumor growth pattern to a multifocal pattern (12 and 13%, p = 0.55). Distant lesions appeared in 17% (BEV/IRI) and 13% (TMZ) of patients (p = 0.69). 15% of patients in the BEV/IRI arm and 8% in the TMZ arm developed a diffuse growth pattern from an initially non-diffuse pattern (p = 0.42). The tumor growth and invasiveness patterns do not differ between BEV/IRI and TMZ-treated MGMT-non-methylated glioblastoma patients in the GLARIUS trial. BEV/IRI was not associated with an increased rate of multifocal, distant, or highly invasive tumors at the time of recurrence.
Item Type: | Journal article |
---|---|
Faculties: | Medicine |
Subjects: | 600 Technology > 610 Medicine and health |
ISSN: | 0171-5216 |
Language: | English |
ID Code: | 63483 |
Deposited On: | 19. Jul 2019 12:13 |
Last Modified: | 04. Nov 2020 13:42 |
- BASE
- Schaub, Christina
- Kebir, Sied
- Junold, Nina
- Hattingen, Elke
- Schäfer, Niklas
- Steinbach, Joachim P.
- Weyerbrock, Astrid
- Hau, Peter
- Goldbrunner, Roland
- Niessen, Michael
- Mack, Frederic
- Stuplich, Moritz
- Tzaridis, Theophilos
- Bähr, Oliver
- Kortmann, Rolf-Dieter
- Schlegel, Uwe
- Schmidt-Graf, Friederike
- Rohde, Veit
- Braun, Christian
- Haenel, Mathias
- Sabel, Michael
- Gerlach, Rüdiger
- Krex, Dietmar
- Belka, Claus
- Vatter, Hartmut
- Pröscholdt, Martin
- Herrlinger, Ulrich
- Glas, Martin
- Google Scholar
- Schaub, Christina
- Kebir, Sied
- Junold, Nina
- Hattingen, Elke
- Schäfer, Niklas
- Steinbach, Joachim P.
- Weyerbrock, Astrid
- Hau, Peter
- Goldbrunner, Roland
- Niessen, Michael
- Mack, Frederic
- Stuplich, Moritz
- Tzaridis, Theophilos
- Bähr, Oliver
- Kortmann, Rolf-Dieter
- Schlegel, Uwe
- Schmidt-Graf, Friederike
- Rohde, Veit
- Braun, Christian
- Haenel, Mathias
- Sabel, Michael
- Gerlach, Rüdiger
- Krex, Dietmar
- Belka, Claus
- Vatter, Hartmut
- Pröscholdt, Martin
- Herrlinger, Ulrich
- Glas, Martin